Search results - 10 results
Protocol for a systematic review and meta-analysis of the diagnostic test accuracy of host and HPV DNA methylation in cervical cancer screening and management.
a test to diagnose cervical intraepithelial neoplasia (CIN); we present a protocol to evaluate the accuracy of methylation markers to detect high-grade CIN and cervical cancer. METHODS AND ANALYSIS: We ...
Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
of 13 high-risk (hr) HPV s. OncoPredict HPV ® SCR (index assay) identifies HPV-16 and HPV-18 separately, 11 other hrHPV in aggregate and includes quality controls for sample adequacy, DNA extraction ...
Tackling cervical cancer in Europe amidst the COVID-19 pandemic.
COVID-19 pandemic might also generate opportunities for more efficient prevention, by promoting more cost-effective, evidence-based protocols, by focusing on women who are at high-risk, extending HPV testing ...
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.
as Topic Sensitivity and Specificity specimen handling Uterine Cervical Dysplasia Uterine Cervical Neoplasms Vagina Vaginal Smears Abstract: OBJECTIVE: To evaluate the diagnostic accuracy of high-risk ...
Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.
Cochrane database of Systematic reviews. A summary of this Cochrane review is presented below. Areas covered: Only trials involving mono-, bi-, and quadrivalent HPV vaccines were included. Trials evaluating ...
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
assays are foreseen to be evaluated: RealTime High Risk HPV assay (Abbott), cobas-4800 and-6800 (Roche), Onclarity (BD), Xpert HPV (Cepheid) and Anyplex II HPV HR (Seegene). CONCLUSION: Given empirical ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
assessment, we considered it as high-risk (hr) HPV positive when at least one of the following HPV types was present: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
+/6+ PCR, with a genotyping readout as an alternative for the more established enzyme immunoassay (EIA) detection of 14 targeted high-risk human papillomavirus (HPV) types. LMNX is additionally provided ...
IPAAC Rapport WP4: Cancer control policy interview survey
provision of structural budgets. Register-based collection of structured and validated data of lifestyles and interventions from electronic data sources in health care would be a key to evaluation and to ...
Chapter 10: HPV testing on cervical cancer specimens: which assay can be used in cervical cancer screening.
screening programmes need to know which HPV tests are credible and have evidence-based performance in primary screening. Systematic reviews have assessed which high-risk HPV DNA tests are sufficiently ...